Back to Search
Start Over
Effects of Maraviroc versus Efavirenz in Combination with Zidovudine-Lamivudine on the CD4/CD8 Ratio in Treatment-Naive HIV-Infected Individuals.
- Source :
-
Antimicrobial agents and chemotherapy [Antimicrob Agents Chemother] 2017 Nov 22; Vol. 61 (12). Date of Electronic Publication: 2017 Nov 22 (Print Publication: 2017). - Publication Year :
- 2017
-
Abstract
- A low CD4/CD8 ratio during treated HIV infection reflects heightened immune activation and predicts death. The effects of different antiretroviral therapy regimens on CD4/CD8 ratio recovery remains unclear. We performed a post hoc analysis of the MERIT study, a randomized, double-blind trial of maraviroc versus efavirenz in combination with zidovudine-lamivudine in treatment-naive HIV-infected individuals. We found higher rates of CD4/CD8 ratio normalization with efavirenz, which was driven by a greater CD8 <superscript>+</superscript> T-cell decline.<br /> (Copyright © 2017 American Society for Microbiology.)
- Subjects :
- Adult
Alkynes
Biomarkers analysis
Cyclopropanes
Double-Blind Method
Drug Administration Schedule
Drug Combinations
Female
HIV Infections immunology
HIV Infections mortality
HIV Infections virology
HIV-1 drug effects
HIV-1 genetics
HIV-1 immunology
Humans
Male
Maraviroc
Middle Aged
RNA, Viral antagonists & inhibitors
RNA, Viral biosynthesis
RNA, Viral genetics
Survival Analysis
Viral Load drug effects
Anti-HIV Agents therapeutic use
Benzoxazines therapeutic use
CD4-CD8 Ratio
Cyclohexanes therapeutic use
HIV Infections drug therapy
Lamivudine therapeutic use
Triazoles therapeutic use
Zidovudine therapeutic use
Subjects
Details
- Language :
- English
- ISSN :
- 1098-6596
- Volume :
- 61
- Issue :
- 12
- Database :
- MEDLINE
- Journal :
- Antimicrobial agents and chemotherapy
- Publication Type :
- Academic Journal
- Accession number :
- 28993335
- Full Text :
- https://doi.org/10.1128/AAC.01763-17